Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Limited has secured Canadian regulatory approval for its CT:VQ™ imaging technology, marking a significant expansion in North America. This approval allows for immediate commercial deployment through Philips’ distribution network, tapping into Canada’s substantial market of over 40 million people and 560 CT scanners. The technology offers clinical and logistical advantages over traditional nuclear VQ imaging, potentially capturing significant market share and driving long-term growth in ventilation-perfusion scans. This milestone, combined with the Philips partnership, positions 4DMedical to rapidly scale revenue and establish CT:VQ™ as the standard of care for VQ imaging across North America.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global leader in respiratory imaging technology, specializing in innovative solutions for lung health. The company is known for its advanced imaging products, such as CT:VQ™, which provide non-contrast, CT-based ventilation-perfusion imaging. 4DMedical focuses on expanding its market presence in North America and has a strategic partnership with Philips for distribution.
Average Trading Volume: 5,122,026
Technical Sentiment Signal: Buy
Current Market Cap: A$1.15B
See more insights into 4DX stock on TipRanks’ Stock Analysis page.